SCHEMBL25751666

SCHEMBL25751666

Cc1cc(C)c(C(C)(C)CC=O)c(OC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(C)(C)C)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.35
MAPT P10636 2/20 0.35
HPGD P15428 2/20 0.35
TSHR P16473 2/20 0.35
LMNA P02545 1/20 0.33
ALOX15 P16050 1/20 0.33
MAPK1 P28482 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
APP P05067 1/20 0.30
CTSK P43235 2/20 0.30
PPARG P37231 1/20 0.30
PPARA Q07869 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25751658 0.88 ALDH1A1 (0.37) ALDH1A1MAPTHPGDTSHRLMNA
SCHEMBL25751669 0.88 ALDH1A1 (0.35) ALDH1A1MAPTHPGDTSHRLMNA
SCHEMBL25751671 0.83 ALDH1A1 (0.34) ALDH1A1MAPTHPGDTSHRLMNA
SCHEMBL17464403 0.80 ALDH1A1 (0.52) ALDH1A1MAPTHPGDTSHRLMNA
SCHEMBL18613698 0.79 MAPT (0.36) ALDH1A1MAPTHPGDTSHRLMNA
SCHEMBL24878406 0.77 MAPT (0.33) ALDH1A1MAPTHPGDTSHRLMNA
SCHEMBL28535446 0.77 ALDH1A1 (0.35) ALDH1A1MAPTHPGDTSHRLMNA
SCHEMBL19608800 0.76 ALOX15 (0.36) ALDH1A1MAPTHPGDTSHRLMNA
SCHEMBL18613700 0.76 TSHR (0.36) ALDH1A1MAPTHPGDTSHRLMNA
SCHEMBL15283358 0.76 ALDH1A1 (0.37) ALDH1A1MAPTHPGDLMNAALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230190797-A1 COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2023-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230190797-A1 COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY HAVCR2, CD4, CCR1 ALDH1A1 890/4885MAPT 1886/4885HPGD 1271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.